Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652112 | 1.00 | GCK (0.35) | GCKDDB1CRBN | |
| SCHEMBL2652108 | 1.00 | GCK (0.35) | GCKDDB1CRBN | |
| SCHEMBL1858753 | 0.83 | MAOA (0.36) | GCK | |
| SCHEMBL1858751 | 0.83 | MAOA (0.36) | GCK | |
| SCHEMBL17330298 | 0.83 | CYP2C19 (0.41) | GCK | |
| SCHEMBL1107471 | 0.80 | GCK (0.39) | GCK | |
| SCHEMBL3387053 | 0.77 | GCK (0.39) | GCK | |
| SCHEMBL2894002 | 0.77 | GCK (0.44) | GCK | |
| SCHEMBL2651112 | 0.77 | GCK (0.44) | GCK | |
| SCHEMBL2651108 | 0.77 | GCK (0.44) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745491-B2 | Substituted phenylacetamides and their use as glucokinase activators | PROSIDION LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | PROSIDION LIMITED (GB) | 2009-02-26 | — | — | US | disclosed |
| US-20080293741-A1 | Tricyclo Substituted Amides as Glucokinase Modulators | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293741-A1 | Tricyclo Substituted Amides as Glucokinase Modulators | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | PROSIDION LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | PROSIDION LIMITED (GB) | 2008-01-17 | — | — | US | disclosed |
| WO-2007051847-A1 | TRICYCLO SUBSTITUTED AMIDES AS GLUCOKINASE MODULATORS | PROSIDION LTD (GB) | 2007-05-10 | — | — | WO | disclosed |
| WO-2006016194-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006016174-A1 | FLUORINATION PROCESS OF PROTECTED AMINOTHIAZOLE | PROSIDION LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005103021-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | PROSIDION LIMITED (GB) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242869-A1 | Tri(Cyclo) Substituted Amide Compounds | IAPP, GPR119, CPT1A | GCK 86/4885DDB1 3381/4885CRBN 3403/4885 |
| US-20080015358-A1 | Fluorination Process of Protected Aminothiazole | GCK, KHK, GCKR | GCK 1/4885DDB1 4386/4885CRBN 4351/4885 |
| US-20090054444-A1 | 2(R)-2-(4-cyclopropanesulfonylphenyl)-N-(1-methylpyrazol-3-yl)-3-((R)-3-oxocyclopentyl)propionamide, useful in the prophylaxis and treatment of hyperglycemia and diabetes; hypoglycemic and antidiabetic agents | GPR119, SLC5A2, SLC5A1 | GCK 37/4885DDB1 2457/4885CRBN 2403/4885 |
| US-20080293741-A1 | Tricyclo Substituted Amides as Glucokinase Modulators | GCK, GCKR, GALK1 | GCK 1/4885DDB1 2632/4885CRBN 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.